Genotyping of <i>RB1</i> status identifies two distinct subtypes in <i>EGFR</i>‐mutant lung cancers with SCLC transformation-Reference-Cited by-同舟云学术

Genotyping of RB1 status identifies two distinct subtypes in EGFR‐mutant lung cancers with SCLC transformation

Published:2024-05 Issue:5 Volume:14 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Huang Jie¹^ORCID,Zhang Shi‐Ling²,Zhang Chao¹,Huang Weiye³,Zhang Zhenhua⁴,Chen Yu‐Qing¹,Su Jun‐Wei¹,Yan Hong‐Hong¹,Chen Hua‐Jun¹,Yang Jin‐Ji¹,Wang Junjian⁴⁵^ORCID,Wu Yi‐Long¹

Affiliation:

1. Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University Guangzhou China

2. Department of Medical Oncology Affiliated Cancer Hospital and Institute of Guangzhou Medical University Guangzhou China

3. Department of Pathology Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University Guangzhou China

4. School of Pharmaceutical Sciences Sun Yat‐sen University Guangzhou China

5. National‐Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Sun Yat‐sen University Guangzhou China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.1683

Reference10 articles.

1. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

2. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

3. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study

4. Evolution and genotypic characteristics of small cell lung cancer transformation in non-small cell lung carcinomas